BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Teva Pharmaceuticals Industries Limited is one of the most undervalued stocks on our list.

TheFly reported on December 9 that Bank of America Securities analyst Jason Gerberry reaffirmed a Buy rating on TEVA and raised his price target to $32.00, reflecting conviction that the stock remains undervalued relative to its improving revenue trajectory and debt reduction progress.

Also on December 9, 2025, Barclays analyst Glen Santangelo initiated coverage of TEVA with an Overweight rating and a $35.00 price target, signaling further Wall Street confidence in Teva’s branded growth drivers and overall strategic progress.

BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight

These analyst moves come amid significant pipeline advancement for Teva Pharmaceuticals Industries Limited (NYSE:TEVA). On December 9, 2025, TEVA submitted a New Drug Application (NDA) to the U.S. FDA for olanzapine long-acting injectable (LAI) for schizophrenia, based on positive Phase 3 SOLARIS trial data supporting its efficacy and safety as a once-monthly subcutaneous formulation. If approved, this asset would expand the company’s branded neuroscience franchise alongside its existing UZEDY (risperidone LAI).

Teva Pharmaceuticals Industries Limited (NYSE:TEVA) is a global leader in the pharmaceutical industry, best known for its robust generics business, which is complemented by a growing portfolio of specialty and innovative medicines.

While we acknowledge the risk and potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.